ASCO 2021 | Progress in treatment approaches for patients with melanoma

Sajeve S. Thomas, MD, Orlando Health UF Health, Orlando, FL, outlines the progress that has been made in the field of melanoma including the use of immunotherapy, immune checkpoint inhibitors, targeted therapies and multiple injectional approaches for treating cancer. Dr Thomas highlights that historically, melanoma was associated with a 6-month life expectancy and patients often did not respond to therapies. Dr Thomas clarifies that tumor-infiltrating lymphocyte (TIL) therapy may represent a novel treatment approach in patients who do not have targetable mutations, as well as those who do not respond to checkpoint inhibitors. This interview was conducted at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.